Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune, muscle and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib (R788), an oral syk inhibitor that is expected to enter phase III clinical trials for rheumatoid arthritis in 2010, and R343, an inhaled syk inhibitor that is in clinical trials for asthma.
Rigel Forward-Looking Statements
This press release contains "forward-looking" statements, including,
without limitation, statements related to plans to pursue further clinical
development of R788 (fostamatinib), including the timing thereof. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words such as
"estimate," "anticipate" and similar expressions are intended to identify
these forward-looking statements. These forward-looking statements are based
upon Rigel's current expectations and involve risks and uncertainties. There
are a number of important factors that could cause Rigel's results to differ
materially from those indicated by these forward-looking statements,
including, without limitation, risks associated with the timing and success
Copyright©2010 PR Newswire.
All rights reserved